Decontamination wipes supplier Hero Wipes revealed on Tuesday that its Hero Wipes products can now remove up to 99.7% of lead contaminants from skin as well as up to 90% of known carcinogens found in soot.
Public safety professionals, including firefighters and law enforcement personnel, are put at great risk daily from exposure to cancer-causing carcinogens. Firefighters responding to structure fires are exposed not only to potentially carcinogenic soot but lead contaminants coming from household furnishings, carpets and appliances, exposure of gunshot residue as well as lack of proper decontamination.
Assembled in the USA and EWG verified, Hero Wipes has been formulated, tested and proven to remove carcinogenic soot and lead contaminants in the same wipe.
Launched in 2017, Hero Wipes is the first on-scene decontamination wipe to have its unique formulation, a patent-pending blend of ingredients that works to isolate harmful toxins and carcinogens, scientifically tested for effectiveness in their removal. Hero Wipes is proven effective to remove up to 90% of benzopyrene, commonly found in soot and up to 69% of TCEP, the most common toxic flame retardant, in just a single swipe.
TuHURA Biosciences acquires Kineta
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Biovica secures European patent for biomarker use in immuno-oncology
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma